<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04281511</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2019-0034</org_study_id>
    <nct_id>NCT04281511</nct_id>
  </id_info>
  <brief_title>A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy</brief_title>
  <official_title>A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Based on the literature, the pancreatic cancer treatment predictor biomarker, which is
           used in the domestic clinical field, is actually applied to the pancreatic cancer
           patient cohort of the National Cancer Center.

        2. To systematically prospectively identify prospective treatment response biomarkers for
           Pancreatic Cancer Cohort in the National Cancer Center
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Immunohistochemistry and gene test for hENT1, DCK, SMAD4, CES2, BRCA 1/2,PALB2, MMRd,
           MSI, Tumor Ag and etc. on Cancer sample

        2. Collect data of Biomarker for pancreatic cancer

        3. Compare with Big data and Cohort study in National cancer center
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 3, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>median survival</measure>
    <time_frame>5 years</time_frame>
    <description>The length of time from either the date of diagnosis or the start of treatment for a disease,the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progressive－free survival</measure>
    <time_frame>5 years</time_frame>
    <description>The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse</description>
  </primary_outcome>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Pancreatic Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      cancer tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pancreatic Cancer Patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically Confirmed Pancreatic Cancer Patients

        Exclusion Criteria:

          -  Subjects who do not agree with the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sangmyung Woo</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sangmyung Woo</last_name>
    <phone>+82 31 920 1733</phone>
    <email>wsm@ncc.re.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong‐gu,</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SANGMYUNG WOO, MD</last_name>
      <phone>82-31-920-1733</phone>
      <email>wsm@ncc.re.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009 Jan;136(1):187-95. doi: 10.1053/j.gastro.2008.09.067. Epub 2008 Oct 7.</citation>
    <PMID>18992248</PMID>
  </results_reference>
  <results_reference>
    <citation>Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Halloran CM, Mayerle J, Oláh A, Jackson R, Rawcliffe CL, Scarpa A, Bassi C, Büchler MW; European Study Group for Pancreatic Cancer. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst. 2014 Jan;106(1):djt347. doi: 10.1093/jnci/djt347. Epub 2013 Dec 3.</citation>
    <PMID>24301456</PMID>
  </results_reference>
  <results_reference>
    <citation>Yamada R, Mizuno S, Uchida K, Yoneda M, Kanayama K, Inoue H, Murata Y, Kuriyama N, Kishiwada M, Usui M, Ii N, Tsuboi J, Tano S, Hamada Y, Tanaka K, Horiki N, Ogura T, Shiraishi T, Takei Y, Katayama N, Isaji S. Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy. Pancreas. 2016 May-Jun;45(5):761-71. doi: 10.1097/MPA.0000000000000597.</citation>
    <PMID>26784908</PMID>
  </results_reference>
  <results_reference>
    <citation>Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, Klein A, Laheru D, Iacobuzio-Donahue CA. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res. 2006 Apr 15;12(8):2492-7. Erratum in: Clin Cancer Res. 2007 Jul 15;13(14):4313. Rubio-Viquiera, Belen [corrected to Rubio-Viqueira, Belen].</citation>
    <PMID>16638857</PMID>
  </results_reference>
  <results_reference>
    <citation>Capello M, Lee M, Wang H, Babel I, Katz MH, Fleming JB, Maitra A, Wang H, Tian W, Taguchi A, Hanash SM. Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. J Natl Cancer Inst. 2015 May 29;107(8). pii: djv132. doi: 10.1093/jnci/djv132. Print 2015 Aug.</citation>
    <PMID>26025324</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 20, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>February 23, 2020</last_update_submitted>
  <last_update_submitted_qc>February 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Sang Myung Woo</investigator_full_name>
    <investigator_title>Chief, Senior Scientist</investigator_title>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Biomarker</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>pharmacogenomic</keyword>
  <keyword>clinical trials</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

